DelveInsight’s, “Peritoneal Cancer Pipeline Insight, 2023,” report provides comprehensive insights about 60+ companies and 60+ pipeline drugs in Peritoneal Cancer pipeline landscape. It covers the Peritoneal Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Peritoneal Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Peritoneal Cancer Pipeline Report

• DelveInsight’s Peritoneal Cancer pipeline report depicts a robust space with 60+ active players working to develop 60+ pipeline therapies for Peritoneal Cancer treatment.
• The leading companies working in the Peritoneal Cancer Market include Shattuck Labs Inc., Corcept Therapeutics, Seagen, Mersana Therapeutics, IMPACT Therapeutics, ImmunoGen, LintonPharm Co. Ltd., Sutro Biopharma Inc., Elucida Oncology, Bio-Path Holdings, Clover BiopharmaceuticalAUS Pty Ltd, Rhizen Pharmaceuticals SA, Oncoinvent, OncoMed Pharmaceuticals, Inc., Ipsen, Green3Bio, and others.
• Promising Peritoneal Cancer Pipeline Therapies in the various stages of development include Adavosertib, Paclitaxel, Carboplatin, Chemotherapy, Rucaparib, and others.
• November 2023: ImmunoGen Inc. announced a study of Phase 2 clinical trials for Mirvetuximab soravtansine and Carboplatin. IMGN853-0420 is a multicenter, open-label, phase 2 study of carboplatin plus mirvetuximab soravtansine followed by mirvetuximab soravtansine continuation in folate receptor-alpha positive, recurrent platinum sensitive, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancer following 1 prior line of platinum-based chemotherapy.
• November 2023: National Cancer Institute (NCI) announced a study of Phase 3 clinical trials for Carboplatin and Cediranib Maleate. This phase III trial studies olaparib or cediranib maleate and olaparib to see how well they work compared with standard platinum-based chemotherapy in treating patients with platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer that has come back. Olaparib and cediranib maleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
• November 2023: Precigne Inc. announced a study of Phase 1 clinical trials for PRGN-3005 UltraCAR-T cells. This is a Phase I/Ib dose escalation, dose expansion, study to evaluate the safety and identify the recommended dose of modified immune cells PRGN-3005 (autologous chimeric antigen receptor (CAR) T cells developed by Precigen, Inc.) in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has spread to other places in the body, that has come back and is resistant to platinum chemotherapy. Autologous CAR T cells are modified immune cells that have been engineered in the laboratory to specifically target a protein found on tumor cells and kill them.
• November 2023: Hoffmann- La Roche announced a study of Phase 4 clinical trials for Bevacizumab. This multicenter prospective study will evaluate the safety and efficacy of Avastin (bevacizumab) in routine clinical practice in patients with advanced/metastatic epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer. Data will be collected from eligible patients until death, withdrawal of consent, loss to follow-up, or study closure.

 

Request a sample and discover the recent advances in Peritoneal Cancer Treatment Drugs @ Peritoneal Cancer Pipeline Report

 

In the Peritoneal Cancer pipeline report, a detailed description of the drug is given which includes the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Peritoneal Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product-related details.

 

Peritoneal Cancer Overview

The invasion of the serous membrane lining the abdominal cavity, viscera, and coelom in amniotes by malignant cells is called peritoneal surface malignancy or peritoneal cancer (PC). It is divided into primary and secondary types. The de novo origin of cancer in the mesothelium of the abdomen causes primary mesothelioma. In contrast, the dissemination of tumor cells in the peritoneal cavity from other sites results in secondary peritoneal cancer.

 

Find out more about Peritoneal Cancer Therapeutics Assessment @ Peritoneal Cancer Preclinical and Discovery Stage Products

 

Peritoneal Cancer Emerging Dugs Profile

• Luvelta (STRO-002): Sutro Biopharma, Inc.
• IMGN151: ImmunoGen
• Catumaxomab: LintonPharm Co. Ltd.

 

Peritoneal Cancer Pipeline Therapeutics Assessment

There are approx. 60+ key companies which are developing the therapies for Peritoneal Cancer. The Peritoneal Cancer companies which have their Peritoneal Cancer drug candidates in the most advanced stage, i.e. Phase III include, ImmunoGen.

 

DelveInsight’s Peritoneal Cancer pipeline report covers around 60+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Peritoneal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

 

Peritoneal Cancer Pipeline Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

 

Learn more about the emerging Peritoneal Cancer Pipeline Therapies @ Peritoneal Cancer Clinical Trials Assessment

 

Scope of the Peritoneal Cancer Pipeline Report

• Coverage- Global
• Peritoneal Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Peritoneal Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Peritoneal Cancer Companies- Shattuck Labs Inc., Corcept Therapeutics, Seagen, Mersana Therapeutics, IMPACT Therapeutics, ImmunoGen, LintonPharm Co. Ltd., Sutro Biopharma Inc., Elucida Oncology, Bio-Path Holdings, Clover BiopharmaceuticalAUS Pty Ltd, Rhizen Pharmaceuticals SA, Oncoinvent, OncoMed Pharmaceuticals, Inc., Ipsen, Green3Bio, and others.
• Peritoneal Cancer Pipeline Therapies- Adavosertib, Paclitaxel, Carboplatin, Chemotherapy, Rucaparib, and others.

 

Dive deep into rich insights for new drugs for Peritoneal Cancer Treatment, Visit @ Peritoneal Cancer Market Drivers and Barriers, and Future Perspective

 

Table of Content

1. Introduction
2. Executive Summary
3. Peritoneal cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Peritoneal cancer– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Catumaxomab: LintonPharm Co.,Ltd.
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Luvelta (STRO-002): Sutro Biopharma, Inc.
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug name: Company Name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Peritoneal cancer Key Companies
21. Peritoneal cancer Key Products
22. Peritoneal cancer- Unmet Needs
23. Peritoneal cancer- Market Drivers and Barriers
24. Peritoneal cancer- Future Perspectives and Conclusion
25. Peritoneal cancer Analyst Views
26. Peritoneal cancer Key Companies
27. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/liver-fibrosis-market